StocksEli Lilly & CoLLY

LLY

Eli Lilly & Co

322.20 -1.14 (-0.35%)
Forsinkede priser fra NASDAQ, i USD Markedet er åpent
Handle
S
322.20
K
323.36
Festet innlegg
Cancer-Med
Eli Lilly’s Retevmo approved by FDA for RET fusion+ advanced/metastatic solid tumours. 👉 $LLY (Eli Lilly & Co) ‘s Retevmo (selpercatinib) has been granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with locally advanced or metastatic solid tumours with a rearranged... Vis flere Oversett
Markedsfeed
Topp